论文部分内容阅读
目的:观察细辛脑治疗成人哮喘患者血清白细胞介素-25(IL-25)、嗜酸性粒细胞阳离子蛋白(ECP)、白细胞介素-27(IL-27)的影响。方法:100例支气管哮喘患者随机分为观察组(55例)和对照组(45例),对照组给予常规对症治疗(吸氧、解痉平喘、抗感染等),观察组在常规治疗基础上加用细辛脑注射液24 mg加入0.9%氯化钠注射液250 ml,ivd,qd,疗程14 d。比较两组临床疗效,检测两组患者血清IL-25、ECP、IL-27治疗前后水平的变化。结果:观察组总有效率为92.7%,高于对照组(P<0.05)。细辛脑可以降低支气管哮喘患者血清IL-25、ECP、IL-27浓度的浓度,差异有统计学意义(P<0.05或0.01)。结论:细辛脑注射液可降低哮喘患者血清中IL-25、ECP、IL-27浓度,抑制炎症细胞生成,可以减轻哮喘患者的气道炎症反应。
Objective: To observe the effects of Asarum on serum interleukin-25 (IL-25), eosinophil cationic protein (ECP) and interleukin-27 (IL-27) in adult asthma patients. Methods: One hundred patients with bronchial asthma were randomly divided into observation group (55 cases) and control group (45 cases). The control group was given conventional symptomatic treatment (oxygen, spasm and asthma, anti-infection, etc.) With Asarone injection 24 mg 0.9% sodium chloride injection 250 ml, ivd, qd, treatment 14 d. The clinical efficacy was compared between the two groups, and the changes of serum IL-25, ECP and IL-27 before and after treatment were detected. Results: The total effective rate in the observation group was 92.7%, higher than that in the control group (P <0.05). Asarone decreased the concentrations of serum IL-25, ECP and IL-27 in patients with bronchial asthma, the difference was statistically significant (P <0.05 or 0.01). Conclusion: Asarone can reduce the concentration of IL-25, ECP and IL-27 in sera of asthmatic patients and inhibit the production of inflammatory cells, which can reduce the airway inflammation in asthmatic patients.